The sepsis and septic shock market is expected to experience significant growth from $3.48 billion in 2020 to $7.5 billion by 2030 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 8%, according to GlobalData, a leading data and analytics company.

GlobalData’s latest report, ‘Sepsis: Global Drug Forecast and Market Analysis to 2030’, reveals that the main driver of growth will be the launch of multiple first-in-class products that directly manage sepsis and septic shock, including monoclonal antibodies (mAbs), new antibiotics, and drugs with novel mechanisms of action.

Emily Martyn, MPH, Infectious Diseases Analyst at GlobalData, comments: “It is estimated that sepsis accounts for one in five deaths globally and the World Health Organization (WHO) has stated that sepsis is a leading cause of death in hospitals. Additionally, sepsis is one of the most expensive conditions to treat in the US care system. However, there has been limited development in the sepsis market within the last two decades. This is further highlighted by the very public withdrawal of Eli Lilly’s Xigris in 2011 following studies showing that it did not show any mortality benefit for septic patients. As of today, generic antibiotics and supportive therapies dominate the market.

“However, there has been much development as of late into new therapies using a range of novel mechanisms of actions. We expect new first-in-class products to be launched during this period, which will create significant growth in this market.”

GlobalData’s report also identifies a high level of unmet need for sepsis and septic shock, which remains an untapped market associated with nearly two million hospitalizations in the US in 2020. The current treatment options have remained to be antibiotics and supportive therapy for the last two decades, with no sepsis specific products that targets the disease itself.

Martyn concludes: “It is likely that several first-in-class products for sepsis and septic shock will coexist simultaneously by 2030, including new biologics and small molecules for the treatment of sepsis and septic shock. However, the global impact of new products in reducing the overall sepsis burden will depend on the cost-effectiveness of these drugs, given that generic drugs currently dominate the market, as well as how the new drugs are eventually integrated into national treatment policies throughout the 7MM.”

*7MM = US, France, Germany, Italy, Spain, UK, and Japan